Empowered Patient Podcast

Monique Elwell, COO and Co-Founder, Storyvine shares insights about how big and small pharma, medical device developers, healthcare providers, health insurance companies and non-profits are using this guided video tool to capture authentic stories from patients which can then be used in telling a broader view of personal experiences. Monique talks about how patients are being encouraged to share intimate, vulnerable moments to help educate researchers as well as those facing similar health challenges.

@StoryvineInc

Storyvine.com

Listen to the podcast here.

Monique Elwell, COO and Co-Founder, Storyvine shares insights about how big and small pharma, medical device developers, healthcare providers, health insurance companies and non-profits are using this guided video tool to capture authentic stories from patients which can then be used in telling a broader view of personal experiences. Monique talks about how patients are being encouraged to share intimate, vulnerable moments to help educate researchers as well as those facing similar health challenges.

@StoryvineInc

Storyvine.com

Download the transcript here

Dr. Yair Saperstein, co-founder and CEO, avoMD is also chief resident in the department of medicine in the New York City Health and Hospital system. Yair talks about the innovative online tool avoMD is developing to provide relevant portions of guidelines so that doctors can get specific help with the clinical scenario at hand. Yair also explains they are creating an ecosystem that is editable by doctors and providing a way for best practices in hospitals to be more accessible with the goal of improving success at point of care.

@avocadoDOC

avoMD.io

Listen to the podcast here.

Dr. Yair Saperstein, co-founder and CEO, avoMD is also chief resident in the department of medicine in the New York City Health and Hospital system. Yair talks about the innovative online tool avoMD is developing to provide relevant portions of guidelines so that doctors can get specific help with the clinical scenario at hand. Yair also explains they are creating an ecosystem that is editable by doctors and providing a way for best practices in hospitals to be more accessible with the goal of improving success at point of care.

@avocadoDOC

avoMD.io

Download the transcript here.

Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform. Gil explains how cell therapies work by providing multi-dimensional solutions and regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing. He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers.

@Athersys #regenerativemedicine #ARDS

Athersys.com

Listen to the podcast here

Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform. Gil explains how cell therapies work by providing multi-dimensional solutions and how regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing. He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers.

@Athersys #regenerativemedicine #ARDS

Athersys.com

Download the transcript here

Jack Stover, CEO, Interpace Biosciences describes the changing landscape of drug development with the introduction of genetic data, creation of advanced diagnostic tests for pancreatic, thyroid, lung and esophageal cancers, and the resulting implications for treatment plans. He also explains their work with big pharma companies in the area of immuno-oncology to determine potential partnerships with other drug candidates.

@InterpaceBIO #IDXG #immunooncology #cancer

Interpace.com

Listen to the podcast here

Jack Stover, CEO, Interpace Biosciences describes the changing landscape of drug development with the introduction of genetic data, creation of advanced diagnostic tests for pancreatic, thyroid, lung and esophageal cancers, and the resulting implications for treatment plans. He also explains their work with big pharma companies in the area of immuno-oncology to determine potential partnerships with other drug candidates.

@InterpaceBIO #IDXG #immunooncology #cancer

Interpace.com

Download the transcript here

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies. David describes how GigaGen's recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need.

#primaryimmunedeficiency #IVIG #antibody #PolyclonalAntibodies

@Gigageninc

GigaGen.com

Listen to the podcast here

Page 1 of the Interview with David Johnson GigaGen

Karen Jagoda:

Welcome to the EmpoweredPatientPodcast.com show. I'm Karen Jagoda, and my guest today is David Johnson. He's the CEO and co-founder of GigaGen, that's G-I-G-A G-E-N.com. And Dave is an inventor, he's an entrepreneur and is an expert in single cell immunology. And we're talking today about IVIG therapies for patients with primary immune deficiencies. And Dave, I want to welcome you to the show today. I really appreciate you taking a few minutes.

David Johnson:

Thank you. Happy to be here.

Karen Jagoda:

So let's start off by just explaining what IVIG is and how medications are made up that are in this form.

David Johnson:

IVIG currently is derived from plasma of human donors. So what happens is thousands of plasma donors go into collection facilities and the facilities collect plasma from these individuals, and then pools of these donors' plasma get subjected to a manufacturing process where antibodies are extracted from the plasma. And believe it or not, this is actually a drug that's given to patients who have immune deficiencies. And what that means is that these are people who can't make enough antibody or don't make the right kinds of antibodies and therefore need these supplements from the plasma of these donors.

Karen Jagoda:

And so why are these therapies so important? People can't get the same benefit from taking some kind of pill?

David Johnson:

No. Well, if you think about it, this is a chronic disease. And so people have this for their entire lives. Most people get diagnosed in their 20s or maybe 30s. And the only other real alternative is to take antibiotics, for example Cipro, for the rest of your life. And as you could imagine, if you take Cipro, it's fairly toxic, and also eventually you get resistant bacteria, actually pretty quickly. So doctors really have no other choice right now but to use these IVIG therapies.

Karen Jagoda:

So part of the reason it's interesting to talk to you is not only the work that you're doing to change the world of IVIG, but also there's a shortage of traditional IVIG therapies across the country. So first, tell us a little bit about why there's a shortage and then how your therapy is aiming to overcome those kind of shortages in the future.

David Johnson:

Yeah, as you can imagine, people are busy and it can be difficult to get donors to go into the collection facilities to donate plasma. You get some financial reimbursement for going and donating, but it can be really difficult to collect enough plasma to create enough antibody that would meet the demand. Another issue is that outside of the US, it can be difficult to collect plasma sometimes because of infectious disease outbreaks. For example, China has difficulty collecting plasma. You can imagine with the coronavirus outbreak, it's going to be even more difficult. Then some places in Europe you can't give people any compensation for plasma donations, so that makes it harder to collect. So all around, there's growing demand for IVIG products, but not really growing plasma supply. So it's a big problem that, somehow it needs to be solved one way or another.

Download the entire transcript.

Sponsored by

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies. David describes how GigaGen's recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need.

#primaryimmunedeficiency #IVIG #antibody #PolyclonalAntibodies

@GigaGeninc

GigaGen.com

Download the entire transcript here

Page 1 of the Interview with David Johnson GigaGen

Karen Jagoda:

Welcome to the EmpoweredPatientPodcast.com show. I'm Karen Jagoda, and my guest today is David Johnson. He's the CEO and co-founder of GigaGen, that's G-I-G-A G-E-N.com. And Dave is an inventor, he's an entrepreneur and is an expert in single cell immunology. And we're talking today about IVIG therapies for patients with primary immune deficiencies. And Dave, I want to welcome you to the show today. I really appreciate you taking a few minutes.

David Johnson:

Thank you. Happy to be here.

Karen Jagoda:

So let's start off by just explaining what IVIG is and how medications are made up that are in this form.

David Johnson:

IVIG currently is derived from plasma of human donors. So what happens is thousands of plasma donors go into collection facilities and the facilities collect plasma from these individuals, and then pools of these donors' plasma get subjected to a manufacturing process where antibodies are extracted from the plasma. And believe it or not, this is actually a drug that's given to patients who have immune deficiencies. And what that means is that these are people who can't make enough antibody or don't make the right kinds of antibodies and therefore need these supplements from the plasma of these donors.

Karen Jagoda:

And so why are these therapies so important? People can't get the same benefit from taking some kind of pill?

David Johnson:

No. Well, if you think about it, this is a chronic disease. And so people have this for their entire lives. Most people get diagnosed in their 20s or maybe 30s. And the only other real alternative is to take antibiotics, for example Cipro, for the rest of your life. And as you could imagine, if you take Cipro, it's fairly toxic, and also eventually you get resistant bacteria, actually pretty quickly. So doctors really have no other choice right now but to use these IVIG therapies.

Karen Jagoda:

So part of the reason it's interesting to talk to you is not only the work that you're doing to change the world of IVIG, but also there's a shortage of traditional IVIG therapies across the country. So first, tell us a little bit about why there's a shortage and then how your therapy is aiming to overcome those kind of shortages in the future.

David Johnson:

Yeah, as you can imagine, people are busy and it can be difficult to get donors to go into the collection facilities to donate plasma. You get some financial reimbursement for going and donating, but it can be really difficult to collect enough plasma to create enough antibody that would meet the demand. Another issue is that outside of the US, it can be difficult to collect plasma sometimes because of infectious disease outbreaks. For example, China has difficulty collecting plasma. You can imagine with the coronavirus outbreak, it's going to be even more difficult. Then some places in Europe you can't give people any compensation for plasma donations, so that makes it harder to collect. So all around, there's growing demand for IVIG products, but not really growing plasma supply. So it's a big problem that, somehow it needs to be solved one way or another.

Download the entire transcript.